Predictive Oncology Inc. (POAI)
Last Price$1.3(9.4%)
Market Cap$8,155.2K
POAI Rating
POAI Quality rating performance
POAI Intrinsic Value
Key Highlights:
As of Mar 03, 2025 POAI Relative Value is $5.1, which is undervalued by 301.8%, compared to current share price of $1.3.
As of Mar 03, 2025 POAI DCF Value is N/A, which is undervalued by N/A, compared to current share price of $1.3.
POAI Share Price History
1W (10.0%)
1M (9.4%)
6M 35.3%
YTD (64.3%)
1Y (57.4%)
3Y (92.2%)
5Y (97.3%)
10Y (100.0%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
POAI Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$8,155.2K
$7,473.2K
$1,379.1K
($12.0M)
Shares Outstanding
6,472K
Employees
N/A
Growth (CAGR)
0.1%
(0.7%)
(44.81%)
10.8%
(21.7%)
(40.23%)
Profitability
7.9%
(958.3%)
(1,013.0%)
(869.8%)
(870.0%)
85.9%
Intrinsic Value
$5.0 (297.3% undervalued)
N/A
$5.0
$174.1
(100.0%)
(22,755.6%)
Valuation (LTM)
Return on Capital
(461.0%)
(154.5%)
(434.5%)
(253.4%)
(158.3%)
(343.9%)
(343.9%)
Financial Health
$3,079.0K
($681.9K)
0.1x
121.9%
Dividends
Earnings
May 13, 2025
MISS by (7.6%)
MISS by 11.1%
44.0%
null Beat & 10 Miss
POAI Stock Financials
POAI Income Statement Metrics
Annual
Quarterly
LTM
POAI Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($13.2M) +6.6% YoY
Capital Expenditure (CAPEX)
($302.4K) -36.4% YoY
Free Cash Flow (FCF)
($13.5M) +5.0% YoY
POAI Income Statement Overview
Annual
Quarterly
LTM
Dec'14
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
$1,780.1K 18.2% YoY
Cost of revenue
$634.8K 25.7% YoY
Operating
expenses
$15.1M (7.0%) YoY
Other: $9,982.4K
POAI Balance Sheet Overview
Annual
Quarterly
LTM
Dec'14
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$14.4M
Current assets ($10.1M, 69.9% of total)
$8,728.7K (60.5%)
$333.7K (2.3%)
Other current assets
$1,016.1K (7.0%)
Non-current assets ($4,338.8K, 30.1% of total)
$0.0 (0.0%)
$3,962.3K (27.5%)
$252.5K (1.8%)
Other non-current assets
$124.1K (0.9%)
Financial position
($5,871.8K)
Cash & Short-term
Investments
Total Debt
POAI Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
POAI Earnings Surprises
Crunching data... Almost there!
POAI Dividends
POAI Dividend Yield
Crunching data... Almost there!
POAI Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with POAI
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$8,155.2K | 4.2 | $5.0 297.3% undervalued | (57.4%) | $1,379.1K | ($12.0M) | (23.7%) | (870.0%) | 7.9% | (434.5%) | 121.9% | |
$207.3B | 6.9 | $106.1 81.3% overvalued | 41.5% | $8,352.1M | $1,077.2M | 17.2% | 12.9% | 67.5% | 26.8% | 0.0% | |
$66.3B | 6.1 | $262.7 15.0% undervalued | (1.4%) | $20.6B | $2,936.0M | 5.9% | 14.2% | 59.4% | 5.4% | 55.9% | |
$46.6B | 6.4 | $81.3 13.6% overvalued | 9.9% | $9,926.1M | $608.0M | 3.6% | 6.1% | 55.6% | 9.1% | 23.8% | |
$34.6B | 7.6 | $190.6 18.2% overvalued | 29.9% | $4,926.8M | $1,388.4M | 12.9% | 28.2% | 57.9% | 32.9% | 16.0% | |
$18.6B | 5.8 | $92.7 1.2% undervalued | (10.8%) | $3,895.4M | $288.1M | 8.4% | 7.4% | 62.8% | 5.9% | 32.0% | |
$17.9B | 4.7 | $52.7 51.1% undervalued | (16.2%) | $12.9B | $566.0M | (14.0%) | 4.4% | 37.1% | (1.5%) | 191.5% | |
$16.9B | 6.1 | $152.8 33.0% overvalued | (36.3%) | $2,893.1M | $276.4M | (1.9%) | 9.6% | 34.6% | 18.6% | 11.3% | |
$14.7B | 7.3 | $131.7 108.2% undervalued | (15.2%) | $4,038.9M | $1,135.5M | 1.8% | 28.1% | 56.2% | 13.2% | 1.0% | |
$10.4B | 5.2 | $139.9 26.6% overvalued | 50.3% | $2,094.4M | $145.3M | 2.3% | 6.9% | 48.0% | (14.8%) | 69.2% | |
$9,757.8M | 6.5 | $174.5 19.0% undervalued | 4.2% | $3,582.9M | $349.2M | 2.7% | 9.7% | 48.7% | 12.0% | 27.7% |
FAQ
What is Predictive Oncology Inc. (POAI) stock rating?
As of today, Predictive Oncology Inc. has a stock rating of 4 (out of 10), which is considered Good.
is Predictive Oncology Inc. (POAI) a good stock to buy?
As of today, Predictive Oncology Inc. has a Good stock rating, which is 297.3% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.